MPM BioImpact’s ADC Therapeutics ADCT Stock Holding History

MPM BioImpact’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-334,384	Closed	-$1.61M	–	34
2022 Q3	$1.61M	Hold	334,384	–	–	0.38%	35
2022 Q2	$2.66M	Hold	334,384	–	–	0.74%	29
2022 Q1	$4.91M	Sell	334,384 -3,012	-0.9%	-$47.8K	1.32%	21
2021 Q4	$6.82M	Sell	337,396 -7,123	-2%	-$172K	1.24%	21
2021 Q3	$9.36M	Buy	344,519 +126,492	+58%	+$3.24M	1.45%	16
2021 Q2	$5.31M	Hold	218,027	–	–	0.87%	14
2021 Q1	$5.32M	Sell	218,027 -321,621	-60%	-$9.32M	0.67%	13
2020 Q4	$17.3M	Hold	539,648	–	–	3.03%	10
2020 Q3	$17.8M	Hold	539,648	–	–	4.29%	8
2020 Q2	$25.3M	Buy	+539,648	New	+$20.5M	6.72%	7

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MPM BioImpact's ADCT Position: Q4 2022 in Review

MPM BioImpact sold out of ADC Therapeutics (ADCT) in Q4 2022, closing a stake of 334,384 shares — an estimated $1.61M sold.

MPM BioImpact first reported a position in ADCT in Q2 2020 and held it in 10 quarters. The position peaked at $25.3M in Q2 2020. 60 funds tracked by Wall St. Rank hold ADCT as of Q4 2022.

MPM BioImpact reported no remaining ADC Therapeutics position as of Q4 2022 after selling out during the quarter.
MPM BioImpact sold 334,384 ADC Therapeutics shares in Q4 2022, an estimated $1.61M.
MPM BioImpact first reported a position in ADC Therapeutics in Q2 2020 and held it in 10 quarters.
MPM BioImpact's ADC Therapeutics position peaked at $25.3M in Q2 2020.
60 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2022.

Based on MPM BioImpact's 13F filing for Q4 2022, filed 14 Feb 2023.